Advice of the amendment to the pricing of eribulin (Halaven^®) pharmaceutical items

Page last updated: 10 December 2018

Amendment to the pricing of eribulin pharmaceutical items for 1 December 2018.

Please note the following corrections to the price of eribulin in the 1 December 2018 Schedule of Pharmaceutical Benefits. The items affected include;

• items 10140Q and 11199K eribulin mesilate 1 mg/2 mL injection, 2 mL vial dispensed price for maximum amount of 3 mg should be $853.74 not $1492.56 as noted in the Schedule, and;
• 10144X and 11212D eribulin mesilate 1 mg/2 mL injection, 2 mL vial dispensed price for maximum amount of 3 mg should be $804.44 not $1434.44 as noted in the Schedule. 

These errors will be amended in the 1 January 2019 Pharmaceutical Benefits Schedule.